7 Key Benefits of Baricitinib for Human Immunity
Baricitinib, LY3009104, JAK inhibitor, JAK1/JAK2, JAK-STAT pathway, immune regulation, rheumatoid arthritis, alopecia areata, COVID-19, cytokine storm, atopic dermatitis, eczema, API, pharmaceutical raw material, Shaanxi Sunrise
Content
7 Key Benefits of Baricitinib for Human Immunity
The transition from broad-spectrum immunosuppressants to highly targeted intracellular signaling inhibitors represents a structural evolution in modern immunopharmacology.
For decades, the management of severe autoimmune disorders relied on large-molecule biologics, which introduce severe cold-chain logistics challenges and long-term immunogenicity risks. Baricitinib (LY3009104) fundamentally disrupts this paradigm as a stable, small-molecule API.
Corporate Positioning: Shaanxi Sunrise Pharmaceutical Co., Ltd. operates exclusively as a primary source manufacturer of Active Pharmaceutical Ingredients (APIs). We supply Baricitinib in bulk powder form for global laboratory research and commercial drug manufacturing. We do not manufacture or supply finished retail pharmaceuticals.
Pharmacological & Clinical Advantages
Evaluating the multi-therapeutic potential of selective JAK inhibition.
01
Highly Selective JAK1 & JAK2 Modulation
Unlike conventional non-selective agents that globally suppress fundamental T-cell and B-cell activity, Baricitinib demonstrates profound selectivity for JAK1 and JAK2 over JAK3. This distinct affinity preserves natural killer (NK) cell function and broader lymphocyte development, ensuring a superior safety profile during chronic formulation administration.
02
Radiographic Preservation in Rheumatoid Arthritis
The ultimate clinical objective in RA management extends beyond localized symptomatic relief to halting structural joint destruction. By robustly suppressing the IL-6 signaling cascade at the intracellular level, Baricitinib heavily downregulates osteoclast activation, thereby preventing irreversible bone and cartilage erosion.
03
Restoration of Follicular Immune Privilege
Alopecia Areata manifests through the collapse of the hair follicle's immune privilege. Baricitinib demonstrates high efficacy by intercepting the IFN-γ signaling loop that sustains this CD8+ T-cell-mediated autoimmune attack, allowing the follicle to safely transition back into the anagen (growth) phase.
04
Attenuation of Systemic Cytokine Storms
In acute intensive care scenarios, pathogenic hyperinflammation often causes more mortality than the initial viral insult. Baricitinib provides a dual mechanism of action: potent systemic anti-inflammatory regulation combined with the potential reduction of viral endocytosis via AAK1 inhibition.
05
Interruption of the Dermatological Pruritus Cycle
Chronic pruritus in Atopic Dermatitis is heavily mediated by the cytokine IL-31, which requires the JAK pathway for signal transduction. Sourcing high-purity Baricitinib API allows formulators to block this specific neural pathway, providing rapid itch relief and facilitating natural epidermal barrier repair.
06
Superior Oral Pharmacokinetics vs. Biologics
As a stable synthetic compound, Baricitinib achieves approximately 79% oral bioavailability. More importantly, it completely eliminates the risk of Anti-Drug Antibodies (ADAs) generation, which often leads to the gradual loss of clinical efficacy commonly observed in long-term monoclonal antibody therapies.
07
Exceptional Solid-Dose Manufacturing Stability
For Contract Manufacturing Organizations (CMOs), formulation feasibility is critical. High-purity Baricitinib bulk powder exhibits exceptional thermal and chemical resilience during aggressive pharmaceutical processing (granulation, compression, and film coating), making it an ideal candidate for scalable solid oral dosage forms.
Verified Analytical Parameters
| Chemical Nomenclature | 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile |
|---|---|
| CAS Registry Number | 1187594-19-7 |
| Molecular Formula / Weight | C16H17N7O2S | 371.42 g/mol |
| Bulk API Purity (HPLC) | ≥ 99.5% (Strict Internal Quality Standards) |
| Physical State | White to off-white high-density crystalline powder |
Procurement & Quality Control FAQ
Does Shaanxi Sunrise supply finished Baricitinib capsules or tablets?
No. We operate strictly as an upstream manufacturer of Active Pharmaceutical Ingredients (APIs). We supply raw Baricitinib in bulk powder drums. Our clients are pharmaceutical manufacturers, compounding facilities, and R&D institutions who utilize our raw materials to engineer their own finished therapeutic products.
What analytical documentation accompanies a bulk API shipment?
Rigorous, transparent quality control is the foundation of our B2B operations. Every commercial and pilot batch is shipped with a comprehensive Certificate of Analysis (COA), detailed High-Performance Liquid Chromatography (HPLC) purity chromatograms, H-NMR structural verification spectra, and a complete Material Safety Data Sheet (MSDS).
Can you accommodate small-scale Minimum Order Quantities (MOQ) for lab research?
Absolutely. We understand that drug development pipelines require staged scalability. While our manufacturing infrastructure handles high-tonnage commercial runs, our sales and technical teams fully support early-stage formulation R&D, offering MOQs ranging from gram-scale up to 1kg for pilot and stability testing phases.